Effect of MGRNOX Index-Guided General Anesthesia on Opioid Consumption in Patients

Launched by PEKING UNIVERSITY SHENZHEN HOSPITAL · May 26, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating how a new method of monitoring pain during surgery, called the MGRNOX index, can help reduce the amount of opioid medication used for pain relief in patients undergoing laparoscopic cholecystectomy, which is a type of surgery to remove the gallbladder. The goal is to see if using this monitoring system can lead to less reliance on opioids, a class of strong painkillers, during anesthesia. Since managing pain effectively is very important in surgery, this study hopes to find a better way to do it.

To be eligible for the study, participants need to be between 18 and 64 years old and scheduled for this specific type of surgery. They should be in generally good health with no significant medical issues, and they should not have a history of drug or alcohol abuse or other serious health conditions. Participants can expect to receive the standard care for anesthesia during their surgery, but with the added benefit of the MGRNOX index monitoring. This is important because it aims to improve pain management and potentially reduce the side effects associated with higher opioid use.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years old and \< 65 years old；
• • American Society of Anesthesiologists (ASA) class I-II；
• • Scheduled to undergo elective laparoscopic cholecystectomy undergeneral anesthesia （without epidural anesthesia, local blocks, or infiltration）
• Exclusion Criteria:
• • Pregnancy or lactation period；
• • BMI ≥35 kg/m² or \<18.5 kg/m²；
• • Anticipated difficult airway；
• • Previous diagnosis of hypertension；
• • History of drug or alcohol abuse within the past 6 months；
• • Preoperative acute or chronic pain history (routine preoperative use of opioid or non-opioid analgesics), peripheral or central nervous system-related disorders；
• • Definitively diagnosed psychiatric disorders or other neuropsychiatric conditions severely affecting cognitive judgment, history of psychotropic medication use；
• • Allergy or intolerance to anesthetic agents；
• • Baseline mean arterial pressure (MAP) \<60 mmHg or \>120 mmHg; baseline heart rate (HR) \<45 bpm or \>90 bpm (Baseline values defined as first measurement taken in the ward after admission)；
• • History of severe underlying diseases (untreated or ongoing peripheral/central cardiovascular diseases, severe hepatic disorders with elevated bilirubin/INR or hypoalbuminemia, severe renal diseases with elevated creatinine, severe pulmonary diseases potentially causing acute respiratory failure or persistent dyspnea)；
• • Implanted pacemaker, chronic arrhythmia, preoperative use of prescribed anticholinergics, α2-adrenergic agonists, beta-1 adrenergic antagonists, or antiarrhythmic medications.